119 related articles for article (PubMed ID: 38767937)
1. Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017).
Guidetti C; De Martin S; Serra G; Apicella M; Pani L; Pappagallo M; Mattarei A; Folli F; Manfredi P; Fava M
J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38767937
[No Abstract] [Full Text] [Related]
2. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M; Stahl SM; Pani L; De Martin S; Cutler AJ; Maletic V; Gorodetzky CW; Vocci FJ; Sapienza FL; Kosten TR; Kröger C; Champasa P; O'Gorman C; Guidetti C; Alimonti A; Comai S; Mattarei A; Folli F; Bushnell D; Traversa S; Inturrisi CE; Manfredi PL; Pappagallo M
J Clin Psychiatry; 2024 Jun; 85(3):. PubMed ID: 38917366
[No Abstract] [Full Text] [Related]
3. Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder.
Guidetti C; Serra G; Pani L; Pappagallo M; Maglio G; Martin S; Mattarei A; Folli F; Manfredi PL; Fava M
Prim Care Companion CNS Disord; 2023 Feb; 25(1):. PubMed ID: 36821775
[No Abstract] [Full Text] [Related]
4. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Fava M; Stahl S; Pani L; De Martin S; Pappagallo M; Guidetti C; Alimonti A; Bettini E; Mangano RM; Wessel T; de Somer M; Caron J; Vitolo OV; DiGuglielmo GR; Gilbert A; Mehta H; Kearney M; Mattarei A; Gentilucci M; Folli F; Traversa S; Inturrisi CE; Manfredi PL
Am J Psychiatry; 2022 Feb; 179(2):122-131. PubMed ID: 34933568
[No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
6. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
8. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
10. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
12. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
Cusin C; Iovieno N; Iosifescu DV; Nierenberg AA; Fava M; Rush AJ; Perlis RH
J Clin Psychiatry; 2013 Jul; 74(7):e636-41. PubMed ID: 23945458
[TBL] [Abstract][Full Text] [Related]
17. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
Jain R; Chen D; Edwards J; Mathews M
Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
20. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
